



54540-Review.docx

Quotes Excluded
Bibliography Excluded8%
SIMILAR

Name of Journal: *World Journal of Diabetes*

Manuscript NO: 54540

Manuscript Type: REVIEW

Sodium-glucose cotransporter 2 inhibitors' mechanisms of action in heart failure

Grubić Rotkvić P *et al.* SGLT2 inhibitors in heart failure

Petra Grubić Rotkvić, Maja Cigrovski Berković, Nikola Bulj, Luka Rotkvić, Ivana Čelap

Match Overview

1	Crossref 119 words Petra Grubić Rotkvić, Maja Cigrovski Berković, Nikola Bu ... Luka Rotkvić. "Minireview: are SGLT2 inhibitors heart save	3%
2	Crossref 60 words Petra Grubić Rotkvić, Maja Cigrovski Berković, Luka Rotkvi ... ć, Nikola Bulj. "Prevention of cardiac allograft vasculopat!	2%
3	Internet 38 words crawled on 04-Aug-2019 link.springer.com	1%
4	Internet 24 words crawled on 29-Mar-2018 circ.ahajournals.org	1%
5	Internet 21 words crawled on 29-Apr-2020 bmjopen.bmj.com	1%
6	Internet 17 words crawled on 18-Jan-2020 cardiab.biomedcentral.com	<1%

Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure ...
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523047>

Dec 26, 2018 · **Heart failure** is a common complication in patients with diabetes, and people with both conditions present a worse prognosis. Sodium–glucose cotransporter 2 **inhibitors** (SGLT2Is) increase urinary glucose excretion, improving glycaemic control.

Cited by: 1 **Author:** Juan Tamargo
Publish Year: 2019

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure ...
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846470>

Oct 24, 2017 · While the potential **mechanisms** responsible for differences in risk rates between members of this drug class for lower **extremity amputations** are not known, it may be relevant to recognize that canagliflozin has less **SGLT2 selectivity** compared to the other currently available **SGLT2 inhibitors**, and this may as a consequence induce more glucosuria 98. While it is not yet known if this translates to greater volume depletion with canagliflozin, a more pronounced rise in **hematocrit** ...

Cited by: 155 **Author:** Yuliya Lytvyn, Petter Bjornstad, Jacob A. Ud...
Publish Year: 2017

SGLT-2 Inhibitors in Heart Failure: Current Management ...
<https://www.ahajournals.org/doi/10.1161/JAHA.119.013389>

Whether **SGLT-2 inhibitors** can be beneficial in the treatment of HF remains to be elucidated; efficacy in the prevention of HF does not necessarily translate to efficacy in the treatment of HF—the GISSI-HF (GISSI **Heart Failure**) and CORONA (Controlled Rosuvastatin Multinational Trial in **Heart Failure**) trials exemplify this notion.

Cited by: 4 **Author:** Carolyn S. P. Lam, Chanchal Chandramouli,...
Publish Year: 2019

Summary | Understanding the mechanisms of SGLT2 inhibition ...
<https://pace-cme.org/2018/07/31/summary...> ▾

May 28, 2018 · **SGLT2 inhibitors** lead to reduction of sugar reabsorption in the proximal tubule. In diabetes patients, **SGLT2** is upregulated, so that 90% of the sugar is reabsorbed early on in the proximal tubule. **SGLT2 inhibitors** suppress this **mechanism**,...

SGLT2 inhibitors and mechanisms of cardiovascular benefit ...
<https://link.springer.com/article/10.1007/s00125-018-4670-7> ▾

Aug 22, 2018 · SGLT2 inhibitors have emerged as powerful pharmacological tools in the prevention of heart failure, with the suggestion that, unlike with other **glucose-lowering agents** [64], this benefit may be observed across the spectrum of people with **type 2 diabetes** with and without established **cardiovascular disease**.

Cited by: 148 **Author:** Subodh Verma, John J. V. McMurray
Publish Year: 2018

Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure
<https://www.sciencedirect.com/science/article/pii/S0002914919310070>

Unlike other **antihyperglycemic drugs**, reduction in hospitalization for heart failure (HF) was also seen as a class effect with this group, **mechanisms** of which are probably multifactorial. Subgroup analysis from these major trials indicated a reduction in progression of nephropathy and HF readmission with **SGLT2 inhibitors**.

Cited by: 3 **Author:** Raktim K. Ghosh, Gopal Chandra Ghosh, M...
Publish Year: 2019

PEOPLE ALSO ASK

- What can SGLT-2 inhibitors do for the Cardiovascular Patient? ▾
- Should cardiologist prescribe a SGLT-2 inhibitor? ▾
- Do SGLT2 inhibitors like Invokana cause ketoacidosis? ▾
- Do SGLT2 inhibitors cause kidney damage? ▾

Feedback

Effect SGLT2 inhibitors on heart failure by sodium ...
<https://pace-cme.org/2017/08/10/effect-sgl2...> ▾

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the only class of agents of which is reported to decrease the risk of cardiovascular events primarily through **risk reduction** of **heart failure** (HF) development or progression and not by reducing risk of myocardial infarction or stroke...

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure ...
<https://www.ahajournals.org/doi/full/10.1161/circulationaha.117.030012>

Treatment of T2D patients with **SGLT2 inhibitors** typically reduces **systolic blood pressure** by 4 to 6 mm Hg and diastolic blood pressure by 1 to 2 mm Hg. 45,46 In response to **SGLT2 inhibition**, similar magnitudes in **systolic blood pressure reduction** (≈2.7 mm Hg)...

Cited by: 155 **Author:** Yuliya Lytvyn, Petter Bjornstad, Jacob A. Ud...
Publish Year: 2017

A new class of drugs for heart failure: SGLT2 inhibitors ...
<https://www.sciencedirect.com/science/article/pii/S0914508717303477>

Sodium glucose cotransporter 2 (SGLT2) inhibitors protect the cardiovascular system beyond lowering blood glucose. A common feature of **type 2 diabetes mellitus** (T2DM) is chronic activation of the sympathetic nervous system. The **kidney** is the epicenter of sympathetic overactivity in T2DM and **heart failure**.

Cited by: 53 **Author:** Motoaki Sano
Publish Year: 2018

Practical Guide to Prescribing ... - JACC: Heart Failure
[heartfailure.onlinejacc.org/content/7/2/169](https://www.sciencedirect.com/science/article/pii/S0914508717303477) ▾

Feb 01, 2019 · The **sodium-glucose cotransporter 2** (SGLT2) inhibitors are a class of glucose-lowering therapies that have been shown to reduce risks of **heart failure** (HF) events in patients with type 2 diabetes mellitus (T2DM) at high-risk for or with cardiovascular disease.

Cited by: 5 **Author:** Orly Vardeny, Muthiah Vaduganathan
Publish Year: 2019

Related searches for SGLT2 inhibitors' mechanisms of action in h...

- sglt2 inhibitors mechanism of action
- sglt2 inhibitors **and** heart failure
- sglt2 inhibitors heart failure **trials**
- sglt2 inhibitors heart failure **nejm**
- sglt 2** inhibitors heart failure
- sglt2 inhibitors heart **disease**
- effects** of sglt2 inhibitors
- review** of sglt2 inhibitors

See results for

SLC5A2 (Protein)

The sodium/glucose cotransporter 2 (SGLT2) is a protein that in humans is encoded by the SLC5A2 (solute carrier fa...



Sodium-glucose cotransporter 2 inhibitors' mechanisms



ALL

IMAGES

VIDEOS

40,500 Results

Any time ▼

Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523047>

Dec 26, 2018 · **Sodium–glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion**, improving **glycaemic control**. In type 2 diabetes (T2D), some SGLT2Is reduce major cardiovascular events, **heart failure hospitalisations** and worsening of **kidney function** independent of glycaemic control.

Cited by: 1

Author: Juan Tamargo

Publish Year: 2019

Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure ...

<https://www.ncbi.nlm.nih.gov/pubmed/31131034>

Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion, improving **glycaemic control**. In type 2 diabetes (T2D), some SGLT2Is reduce major cardiovascular events, **heart failure hospitalisations** and worsening of **kidney function** ...

Cited by: 1

Author: Juan Tamargo

Publish Year: 2019



Sodium-glucose cotransporter 2 inhibitors' mechan



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING


42,800 Results

Any time ▾

Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: **Potential Mechanisms of Action, Adverse Effects and Future Developments.** Tamargo J(1).

Author information: (1)Department of Pharmacology and Toxicology, School of Medicine, Universidad

Complutense, CIBERCV Madrid, Spain. **Heart failure** is a common complication in patients with diabetes, and people with both conditions present a worse prognosis.



Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure ...

www.ncbi.nlm.nih.gov/pubmed/31131034

Was this helpful?

Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523047>

Dec 26, 2018 · **Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion**, improving **glycaemic control**. In type 2 diabetes (T2D), some SGLT2Is reduce major cardiovascular events, **heart failure hospitalisations** and worsening of **kidney function** independent of glycaemic control.

Cited by: 1

Author: Juan Tamargo

Publish Year: 2019

Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure ...

<https://www.ncbi.nlm.nih.gov/pubmed/31131034>

Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion, improving **glycaemic control**. In type 2 diabetes (T2D), some SGLT2Is reduce major cardiovascular events, **heart failure hospitalisations** and worsening of **kidney function** ...

Cited by: 1

Author: Juan Tamargo

Publish Year: 2019